Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (852)	11/17/2003 10:06:16 AM
From: tuck	Read Replies (1) \| Respond to of 1005

>>GAITHERSBURG, Md., Nov. 17 /PRNewswire-FirstCall/ -- GenVec, Inc. (Nasdaq: GNVC - News), a biopharmaceutical company, announced that Peter A. Campochiaro, M.D., Professor of Ophthalmology and Neuroscience, Wilmer Eye Institute, Johns Hopkins School of Medicine and Principal Investigator for the Company's clinical study of AdPEDF, presented an update on the progress of the Phase 1 trial evaluating AdPEDF for safety in patients with wet age-related macular degeneration (AMD) at a symposia of the American Academy of Ophthalmology Annual Meeting in Anaheim, CA yesterday. The Phase 1, open-label, dose-escalating study was designed to determine the safety of GenVec's AdPEDF product candidate, which produces the Pigment Epithelium-Derived Factor (PEDF) protein, a potent natural antiangiogenic inhibitor, administered locally to the eye. The study has enrolled 6 of 8 cohorts and is expected to complete enrollment in the first quarter of 2004. In the 18 patients enrolled to date, AdPEDF was well tolerated with no dose limiting toxicities (DLTs) or severe adverse events (SAEs). The study is being conducted at six sites nationwide including the Wilmer Eye Institute at Johns Hopkins Hospital, Jules Stein Eye Institute at UCLA, the Kresge Eye Institute at Wayne State University, the Casey Eye Institute at Oregon Health & Science University, the University of Washington School of Medicine, and the Cullen Eye Institute/McPherson Retina Center at Baylor College of Medicine. "GenVec is pleased with the progress of this trial and anticipates completing patient accrual in the near future," commented Lisa Wei, Ph.D., GenVec's Director of Pharmacology and PEDF Team Leader. "These data are promising and substantiate further advancement of the program. We expect to present detailed data on the trial at the Association for Research in Vision and Ophthalmology (ARVO) in April 2004," Dr. Wei concluded.<< snip Cheers, Tuck